This Reading Room is a collaboration between MedPage Today® and:
Advanced stage, age over 35 years, and non-dysgerminoma histology are relevant prognostic factors for survival in stage IC and beyond adult malignant ovarian germ cell tumors (MOGCTs), according to the results of a multicenter international collaborative study.
MOGCTs are rare, aggressive malignancies that predominantly affect young women. Michael J. Seckl, PhD, FRCP, FMedSci, of Charing Cross Hospital in London, and colleagues conducted a retrospective study to better define the prognostic factors and evaluate long-term outcomes in patients with stages IC-IV MOGCTs treated with surgery and chemotherapy.
"To our knowledge, this multicenter study in postpubertal patients with stage IC/M-IV MOGCT is the largest series available and identifies several significant factors associated with adverse CSS [cancer-specific CSS]," the researchers wrote in the Journal of Clinical Oncology.
"This highlights the need for tailored treatment strategies rather than simply employing male GCT protocols," the team continued. "In the second-line setting, HDCT [high-dose chemotherapy] should be considered in those responding to salvage chemotherapy, particularly for YSTs [yolk sac tumors], choriocarcinoma, and mixed MOGCTs histology. Given the potential for late relapses, long-term surveillance is essential. Additional research is necessary to validate and refine our findings and those of others."
